<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03363776</url>
  </required_header>
  <id_info>
    <org_study_id>CA034-001</org_study_id>
    <secondary_id>2017-002199-24</secondary_id>
    <nct_id>NCT03363776</nct_id>
  </id_info>
  <brief_title>An Investigational Immuno-Therapy Study of Experimental Medication BMS-986277 Given Alone and in Combination With Nivolumab in Epithelial Cancers</brief_title>
  <official_title>Phase 1/2a First in Human Study of BMS-986277 Administered Alone and in Combination With Nivolumab in Advanced Epithelial Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate experimental medication BMS-986277 given alone&#xD;
      and in combination with Nivolumab in patients with epithelial cancers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Business objectives have changed&#xD;
  </why_stopped>
  <start_date type="Actual">December 6, 2017</start_date>
  <completion_date type="Actual">November 22, 2019</completion_date>
  <primary_completion_date type="Actual">November 22, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With an Adverse Event (AE)</measure>
    <time_frame>from first dose to 60 days post last dose, assessed up to February 2020 (approx. 26 months)</time_frame>
    <description>Number of participants who experienced an AE during the course of the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With a Serious Adverse Event (SAE)</measure>
    <time_frame>from first dose to 60 days post last dose, assessed up to February 2020 (approx. 26 months)</time_frame>
    <description>Number of participants who experienced a SAE during the course of the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With an Adverse Event (AE) Meeting Protocol-defined Dose Limiting Toxicity (DLT) Criteria</measure>
    <time_frame>from first dose to 60 days post last dose, assessed up to February 2020 (approx. 26 months)</time_frame>
    <description>Number of participants who experienced an AE meeting protocol-defined DLT criteria during the course of the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With an Adverse Event (AE) Leading to Discontinuation</measure>
    <time_frame>from first dose to 60 days post last dose, assessed up to February 2020 (approx. 26 months)</time_frame>
    <description>Number of participants who experienced an AE leading to discontinuation during the course of the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With an Adverse Event (AE) Leading to Death</measure>
    <time_frame>from first dose to 60 days post last dose, assessed up to February 2020 (approx. 26 months)</time_frame>
    <description>Number of participants who experienced an AE leading to death during the course of the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With a Clinical Laboratory Test Abnormality</measure>
    <time_frame>from first dose to 60 days post last dose, assessed up to February 2020 (approx. 26 months)</time_frame>
    <description>Number of participants who experienced a clinical laboratory test abnormality during the course of the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With a Vital Sign Abnormality or Other Safety Biomarkers</measure>
    <time_frame>from first dose to 60 days post last dose, assessed up to February 2020 (approx. 26 months)</time_frame>
    <description>Number of participants who experienced a vital sign abnormality or other safety biomarkers during the course of the study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>at Weeks 8, 16 and 24</time_frame>
    <description>ORR is defined as the proportion of all treated participants whose BOR is either CR or PR. BOR was determined by investigators for the reported data.&#xD;
Estimate of ORR and corresponding 2-sided exact 95% CI using the Clopper-Pearson method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>at Weeks 8, 16 and 24</time_frame>
    <description>DCR includes complete response (CR), partial response (PR), and stable disease (SD).&#xD;
Estimate of DCR and corresponding 2-sided exact 95% CI using the Clopper-Pearson method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Duration of Response (mDOR)</measure>
    <time_frame>at Weeks 8, 16 and 24</time_frame>
    <description>DOR for a participant with a BOR of CR or PR is defined as the time between the date of first response and the date of the first objectively documented tumor progression per RECIST v1.1/PCWG3 or death, whichever occurs first.&#xD;
Estimate by the Kaplan-Meier method and corresponding 2-sided 95% CI using Brookmeyer and Crowley methodology (using log-log transformation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Progression-Free Survival (mPFS)</measure>
    <time_frame>at Weeks 8, 16 and 24, to progression</time_frame>
    <description>PFS for a participant is defined as the time from the first dosing date to the date of first objectively documented disease progression or death due to any cause, whichever occurs first.&#xD;
Estimate by the Kaplan-Meier method and corresponding 2-sided 95% CI using Brookmeyer and Crowley methodology (using log-log transformation) for the median and Greenwood formula for the rate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival Rate (PFSR)</measure>
    <time_frame>at Weeks 8, 16 and 24</time_frame>
    <description>PFS for a participant is defined as the time from the first dosing date to the date of first objectively documented disease progression or death due to any cause, whichever occurs first.&#xD;
Estimate by the Kaplan-Meier method and corresponding 2-sided 95% CI using Brookmeyer and Crowley methodology (using log-log transformation) for the median and Greenwood formula for the rate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>Cycle 1 (Day 1 pre-dose through Day 29, 240 hour), Cycle 2 (Day 1 pre-dose through Day 22, 408 hour); through Follow-up visits</time_frame>
    <description>Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data.&#xD;
Cmax is defined as the maximum observed blood concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>Cycle 1 (Day 1 pre-dose through Day 29, 240 hour), Cycle 2 (Day 1 pre-dose through Day 22, 408 hour); through Follow-up visits</time_frame>
    <description>Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data.&#xD;
Tmax is defined as the time of maximum observed blood concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-T)</measure>
    <time_frame>Cycle 1 (Day 1 pre-dose through Day 29, 240 hour), Cycle 2 (Day 1 pre-dose through Day 22, 408 hour); through Follow-up visits</time_frame>
    <description>Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data.&#xD;
AUC(0-T) is the area under the blood concentration-time curve from time zero to time of last quantifiable concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(INF)</measure>
    <time_frame>Cycle 1 (Day 1 pre-dose through Day 29, 240 hour), Cycle 2 (Day 1 pre-dose through Day 22, 408 hour); through Follow-up visits</time_frame>
    <description>Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data.&#xD;
AUC(INF) is the area under the blood concentration-time curve from time zero extrapolated to infinite time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T-HALF</measure>
    <time_frame>Cycle 1 (Day 1 pre-dose through Day 29, 240 hour), Cycle 2 (Day 1 pre-dose through Day 22, 408 hour); through Follow-up visits</time_frame>
    <description>Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data.&#xD;
T-HALF is defined as the apparent terminal half-life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CLT</measure>
    <time_frame>Cycle 1 (Day 1 pre-dose through Day 29, 240 hour), Cycle 2 (Day 1 pre-dose through Day 22, 408 hour); through Follow-up visits</time_frame>
    <description>Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data.&#xD;
CLT is defined as the total body clearance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vss</measure>
    <time_frame>Cycle 1 (Day 1 pre-dose through Day 29, 240 hour), Cycle 2 (Day 1 pre-dose through Day 22, 408 hour); through Follow-up visits</time_frame>
    <description>Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data.&#xD;
Vss is defined as the volume of distribution at steady-state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz</measure>
    <time_frame>Cycle 1 (Day 1 pre-dose through Day 29, 240 hour), Cycle 2 (Day 1 pre-dose through Day 22, 408 hour); through Follow-up visits</time_frame>
    <description>Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data.&#xD;
Vz is defined as the volume of distribution of the elimination phase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-48)</measure>
    <time_frame>Cycle 1 (from time zero to 48 hours postdose)</time_frame>
    <description>Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data.&#xD;
AUC(0-T) is the area under the blood concentration-time curve from time zero to 48 hours postdose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-8)</measure>
    <time_frame>Cycle 1 (from time zero to 8 hours postdose)</time_frame>
    <description>Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data.&#xD;
AUC(0-T) is the area under the blood concentration-time curve from time zero to 8 hours postdose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C48</measure>
    <time_frame>Cycle 1 at 48 hours postdose</time_frame>
    <description>Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data.&#xD;
C48 is defined as the blood concentration at 48 hours postdose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Css-avg</measure>
    <time_frame>Cycle 1 (from time zero to 48 hours postdose)</time_frame>
    <description>Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data.&#xD;
Css-avg is defined as the average blood concentration over a dosing interval at steady state (AUC[0-48]/48).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AI_AUC</measure>
    <time_frame>Cycle 1 (Day 19, Day 15)</time_frame>
    <description>Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data.&#xD;
AUC accumulation index; ratio of AUC(0-48) on Cycle 1 Day 19 to AUC(0-48) on Cycle 1 Day 15 for monotherapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AI_Cmax</measure>
    <time_frame>Cycle 1 (Day 19, Day 15)</time_frame>
    <description>Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data.&#xD;
Cmax accumulation index; ratio of Cmax on Cycle 1 Day 19 to Cmax on Cycle 1 Day 15 for monotherapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T-HALFeff</measure>
    <time_frame>Cycle 1 (Day 1 pre-dose through Day 29, 240 hour), Cycle 2 (Day 1 pre-dose through Day 22, 408 hour); through Follow-up visits</time_frame>
    <description>Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data.&#xD;
T-HALFeff is defined as effective elimination half-life that explains the degree of accumulation observed for a specific exposure measure (exposure measure includes AUC, Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ctrough</measure>
    <time_frame>Cycle 1 (Day 1 pre-dose through Day 29, 240 hour), Cycle 2 (Day 1 pre-dose through Day 22, 408 hour); through Follow-up visits</time_frame>
    <description>Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data.&#xD;
Ctrough is defined as the trough observed blood concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With a Positive Antibody-Drug-Antibody (ADA) Response</measure>
    <time_frame>Cycle 1 (Day 1 pre-dose through Day 29, 240 hour), Cycle 2 (Day 1 pre-dose through Day 22, 408 hour); through Follow-up visits</time_frame>
    <description>Baseline ADA-positive participant is defined as a participant who has an ADA-detected sample at baseline.&#xD;
ADA-positive participant is a participant with at least 1 ADA-positive sample relative to baseline after initiation of the treatment.&#xD;
Frequency distribution of baseline ADA-positive participants and ADA-positive participants after initiation of the treatment</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986277 administered alone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination Dose Escalation Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986277 administered in combination with Nivolumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination Expansion Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986277 monotherapy with option for subsequent Nivolumab therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BMS-986277</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Combination Dose Escalation Therapy</arm_group_label>
    <arm_group_label>Combination Expansion Therapy</arm_group_label>
    <arm_group_label>Monotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Combination Dose Escalation Therapy</arm_group_label>
    <arm_group_label>Combination Expansion Therapy</arm_group_label>
    <other_name>Opdivo</other_name>
    <other_name>BMS-963558</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please&#xD;
        visit www.BMSStudyConnect.com&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Histological or cytological confirmation of metastatic and/or unresectable metastatic&#xD;
             colorectal, prostate, pancreatic, breast, ovarian, or urothelial carcinoma with&#xD;
             measureable disease for solid tumors per RECIST v1.1 and for prostate carcinoma per&#xD;
             PCWG3&#xD;
&#xD;
          -  Presence of at least 2 lesions: at least one with measurable disease as defined by&#xD;
             RECIST v1.1 for solid tumors and by PCWG3 for prostate carcinoma for response&#xD;
             assessment; at least 1 lesion must be accessible for biopsy in addition to the target&#xD;
             lesion&#xD;
&#xD;
          -  Participants must have received, and then progressed or been intolerant to, at least 1&#xD;
             standard treatment regimen in the advanced or metastatic setting, if such a therapy&#xD;
             exists, and have been considered for all other potentially efficacious therapies prior&#xD;
             to enrollment&#xD;
&#xD;
          -  ECOG performance status less than or equal to 2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants with active central nervous system (CNS) metastases, untreated CNS&#xD;
             metastases, or with the CNS as the only site of disease&#xD;
&#xD;
          -  Participants with carcinomatous meningitis&#xD;
&#xD;
          -  Cytotoxic agents, unless at least 4 weeks have elapsed from last dose of prior&#xD;
             anti-cancer therapy and initiation of study treatment&#xD;
&#xD;
          -  Participants with active, known, or suspected autoimmune disease&#xD;
&#xD;
        Other protocol defined inclusion/exclusion criteria could apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanford Research</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Australia</country>
    <country>Spain</country>
  </removed_countries>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.bmsstudyconnect.com/s/US/English/USenHome</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>December 1, 2017</study_first_submitted>
  <study_first_submitted_qc>December 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 6, 2017</study_first_posted>
  <results_first_submitted>November 20, 2020</results_first_submitted>
  <results_first_submitted_qc>November 20, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 19, 2020</results_first_posted>
  <last_update_submitted>November 20, 2020</last_update_submitted>
  <last_update_submitted_qc>November 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 15, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/76/NCT03363776/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 12, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/76/NCT03363776/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>10 participants randomized and treated</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm A (Part 1)</title>
          <description>BMS-986277 IV 3 X 10^10&#xD;
Cycle 1 of BMS-986277 will be administered as a single IV infusion (D1) before proceeding to sequential dosing (consisting of 3 doses administered on Days 15, 17, and 19). A minimum of 24 hours is required between doses of BMS-986277.</description>
        </group>
        <group group_id="P2">
          <title>Arm B (Part 1)</title>
          <description>BMS-986277 IV 3 X 10^11&#xD;
Cycle 1 of BMS-986277 will be administered as a single IV infusion (D1) before proceeding to sequential dosing (consisting of 3 doses administered on Days 15, 17, and 19). A minimum of 24 hours is required between doses of BMS-986277.</description>
        </group>
        <group group_id="P3">
          <title>Arm C (Part 1)</title>
          <description>BMS-986277 IV 1 X 10^12&#xD;
Cycle 1 of BMS-986277 will be administered as a single IV infusion (D1) before proceeding to sequential dosing (consisting of 3 doses administered on Days 15, 17, and 19). A minimum of 24 hours is required between doses of BMS-986277.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Progressive disease</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study drug toxicity</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm A (Part 1)</title>
          <description>BMS-986277 IV 3 X 10^10&#xD;
Cycle 1 of BMS-986277 will be administered as a single IV infusion (D1) before proceeding to sequential dosing (consisting of 3 doses administered on Days 15, 17, and 19). A minimum of 24 hours is required between doses of BMS-986277.</description>
        </group>
        <group group_id="B2">
          <title>Arm B (Part 1)</title>
          <description>BMS-986277 IV 3 X 10^11&#xD;
Cycle 1 of BMS-986277 will be administered as a single IV infusion (D1) before proceeding to sequential dosing (consisting of 3 doses administered on Days 15, 17, and 19). A minimum of 24 hours is required between doses of BMS-986277.</description>
        </group>
        <group group_id="B3">
          <title>Arm C (Part 1)</title>
          <description>BMS-986277 IV 1 X 10^12&#xD;
Cycle 1 of BMS-986277 will be administered as a single IV infusion (D1) before proceeding to sequential dosing (consisting of 3 doses administered on Days 15, 17, and 19). A minimum of 24 hours is required between doses of BMS-986277.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="3"/>
            <count group_id="B4" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61" spread="2.4"/>
                    <measurement group_id="B2" value="59" spread="10.4"/>
                    <measurement group_id="B3" value="47" spread="12.1"/>
                    <measurement group_id="B4" value="57" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&gt; 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&lt;= 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With an Adverse Event (AE)</title>
        <description>Number of participants who experienced an AE during the course of the study.</description>
        <time_frame>from first dose to 60 days post last dose, assessed up to February 2020 (approx. 26 months)</time_frame>
        <population>All treated participants&#xD;
Study terminated, data not reported due to privacy reasons</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Part 1)</title>
            <description>BMS-986277 IV 3 X 10^10&#xD;
Cycle 1 of BMS-986277 will be administered as a single IV infusion (D1) before proceeding to sequential dosing (consisting of 3 doses administered on Days 15, 17, and 19). A minimum of 24 hours is required between doses of BMS-986277.</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Part 1)</title>
            <description>BMS-986277 IV 3 X 10^11&#xD;
Cycle 1 of BMS-986277 will be administered as a single IV infusion (D1) before proceeding to sequential dosing (consisting of 3 doses administered on Days 15, 17, and 19). A minimum of 24 hours is required between doses of BMS-986277.</description>
          </group>
          <group group_id="O3">
            <title>Arm C (Part 1)</title>
            <description>BMS-986277 IV 1 X 10^12&#xD;
Cycle 1 of BMS-986277 will be administered as a single IV infusion (D1) before proceeding to sequential dosing (consisting of 3 doses administered on Days 15, 17, and 19). A minimum of 24 hours is required between doses of BMS-986277.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With an Adverse Event (AE)</title>
          <description>Number of participants who experienced an AE during the course of the study.</description>
          <population>All treated participants&#xD;
Study terminated, data not reported due to privacy reasons</population>
          <units>Number of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Study terminated, data not reported due to privacy reasons</measurement>
                    <measurement group_id="O2" value="NA">Study terminated, data not reported due to privacy reasons</measurement>
                    <measurement group_id="O3" value="NA">Study terminated, data not reported due to privacy reasons</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With a Serious Adverse Event (SAE)</title>
        <description>Number of participants who experienced a SAE during the course of the study.</description>
        <time_frame>from first dose to 60 days post last dose, assessed up to February 2020 (approx. 26 months)</time_frame>
        <population>All treated participants&#xD;
Study terminated, data not reported due to privacy reasons</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Part 1)</title>
            <description>BMS-986277 IV 3 X 10^10&#xD;
Cycle 1 of BMS-986277 will be administered as a single IV infusion (D1) before proceeding to sequential dosing (consisting of 3 doses administered on Days 15, 17, and 19). A minimum of 24 hours is required between doses of BMS-986277.</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Part 1)</title>
            <description>BMS-986277 IV 3 X 10^11&#xD;
Cycle 1 of BMS-986277 will be administered as a single IV infusion (D1) before proceeding to sequential dosing (consisting of 3 doses administered on Days 15, 17, and 19). A minimum of 24 hours is required between doses of BMS-986277.</description>
          </group>
          <group group_id="O3">
            <title>Arm C (Part 1)</title>
            <description>BMS-986277 IV 1 X 10^12&#xD;
Cycle 1 of BMS-986277 will be administered as a single IV infusion (D1) before proceeding to sequential dosing (consisting of 3 doses administered on Days 15, 17, and 19). A minimum of 24 hours is required between doses of BMS-986277.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Serious Adverse Event (SAE)</title>
          <description>Number of participants who experienced a SAE during the course of the study.</description>
          <population>All treated participants&#xD;
Study terminated, data not reported due to privacy reasons</population>
          <units>Number of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Study terminated, data not reported due to privacy reasons</measurement>
                    <measurement group_id="O2" value="NA">Study terminated, data not reported due to privacy reasons</measurement>
                    <measurement group_id="O3" value="NA">Study terminated, data not reported due to privacy reasons</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With an Adverse Event (AE) Meeting Protocol-defined Dose Limiting Toxicity (DLT) Criteria</title>
        <description>Number of participants who experienced an AE meeting protocol-defined DLT criteria during the course of the study.</description>
        <time_frame>from first dose to 60 days post last dose, assessed up to February 2020 (approx. 26 months)</time_frame>
        <population>All treated participants&#xD;
Study terminated, data not reported due to privacy reasons</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Part 1)</title>
            <description>BMS-986277 IV 3 X 10^10&#xD;
Cycle 1 of BMS-986277 will be administered as a single IV infusion (D1) before proceeding to sequential dosing (consisting of 3 doses administered on Days 15, 17, and 19). A minimum of 24 hours is required between doses of BMS-986277.</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Part 1)</title>
            <description>BMS-986277 IV 3 X 10^11&#xD;
Cycle 1 of BMS-986277 will be administered as a single IV infusion (D1) before proceeding to sequential dosing (consisting of 3 doses administered on Days 15, 17, and 19). A minimum of 24 hours is required between doses of BMS-986277.</description>
          </group>
          <group group_id="O3">
            <title>Arm C (Part 1)</title>
            <description>BMS-986277 IV 1 X 10^12&#xD;
Cycle 1 of BMS-986277 will be administered as a single IV infusion (D1) before proceeding to sequential dosing (consisting of 3 doses administered on Days 15, 17, and 19). A minimum of 24 hours is required between doses of BMS-986277.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With an Adverse Event (AE) Meeting Protocol-defined Dose Limiting Toxicity (DLT) Criteria</title>
          <description>Number of participants who experienced an AE meeting protocol-defined DLT criteria during the course of the study.</description>
          <population>All treated participants&#xD;
Study terminated, data not reported due to privacy reasons</population>
          <units>Number of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Study terminated, data not reported due to privacy reasons</measurement>
                    <measurement group_id="O2" value="NA">Study terminated, data not reported due to privacy reasons</measurement>
                    <measurement group_id="O3" value="NA">Study terminated, data not reported due to privacy reasons</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With an Adverse Event (AE) Leading to Discontinuation</title>
        <description>Number of participants who experienced an AE leading to discontinuation during the course of the study.</description>
        <time_frame>from first dose to 60 days post last dose, assessed up to February 2020 (approx. 26 months)</time_frame>
        <population>All treated participants&#xD;
Study terminated, data not reported due to privacy reasons</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Part 1)</title>
            <description>BMS-986277 IV 3 X 10^10&#xD;
Cycle 1 of BMS-986277 will be administered as a single IV infusion (D1) before proceeding to sequential dosing (consisting of 3 doses administered on Days 15, 17, and 19). A minimum of 24 hours is required between doses of BMS-986277.</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Part 1)</title>
            <description>BMS-986277 IV 3 X 10^11&#xD;
Cycle 1 of BMS-986277 will be administered as a single IV infusion (D1) before proceeding to sequential dosing (consisting of 3 doses administered on Days 15, 17, and 19). A minimum of 24 hours is required between doses of BMS-986277.</description>
          </group>
          <group group_id="O3">
            <title>Arm C (Part 1)</title>
            <description>BMS-986277 IV 1 X 10^12&#xD;
Cycle 1 of BMS-986277 will be administered as a single IV infusion (D1) before proceeding to sequential dosing (consisting of 3 doses administered on Days 15, 17, and 19). A minimum of 24 hours is required between doses of BMS-986277.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With an Adverse Event (AE) Leading to Discontinuation</title>
          <description>Number of participants who experienced an AE leading to discontinuation during the course of the study.</description>
          <population>All treated participants&#xD;
Study terminated, data not reported due to privacy reasons</population>
          <units>Number of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Study terminated, data not reported due to privacy reasons</measurement>
                    <measurement group_id="O2" value="NA">Study terminated, data not reported due to privacy reasons</measurement>
                    <measurement group_id="O3" value="NA">Study terminated, data not reported due to privacy reasons</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With an Adverse Event (AE) Leading to Death</title>
        <description>Number of participants who experienced an AE leading to death during the course of the study.</description>
        <time_frame>from first dose to 60 days post last dose, assessed up to February 2020 (approx. 26 months)</time_frame>
        <population>All treated participants&#xD;
Study terminated, data not reported due to privacy reasons</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Part 1)</title>
            <description>BMS-986277 IV 3 X 10^10&#xD;
Cycle 1 of BMS-986277 will be administered as a single IV infusion (D1) before proceeding to sequential dosing (consisting of 3 doses administered on Days 15, 17, and 19). A minimum of 24 hours is required between doses of BMS-986277.</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Part 1)</title>
            <description>BMS-986277 IV 3 X 10^11&#xD;
Cycle 1 of BMS-986277 will be administered as a single IV infusion (D1) before proceeding to sequential dosing (consisting of 3 doses administered on Days 15, 17, and 19). A minimum of 24 hours is required between doses of BMS-986277.</description>
          </group>
          <group group_id="O3">
            <title>Arm C (Part 1)</title>
            <description>BMS-986277 IV 1 X 10^12&#xD;
Cycle 1 of BMS-986277 will be administered as a single IV infusion (D1) before proceeding to sequential dosing (consisting of 3 doses administered on Days 15, 17, and 19). A minimum of 24 hours is required between doses of BMS-986277.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With an Adverse Event (AE) Leading to Death</title>
          <description>Number of participants who experienced an AE leading to death during the course of the study.</description>
          <population>All treated participants&#xD;
Study terminated, data not reported due to privacy reasons</population>
          <units>Number of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Study terminated, data not reported due to privacy reasons</measurement>
                    <measurement group_id="O2" value="NA">Study terminated, data not reported due to privacy reasons</measurement>
                    <measurement group_id="O3" value="NA">Study terminated, data not reported due to privacy reasons</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With a Clinical Laboratory Test Abnormality</title>
        <description>Number of participants who experienced a clinical laboratory test abnormality during the course of the study.</description>
        <time_frame>from first dose to 60 days post last dose, assessed up to February 2020 (approx. 26 months)</time_frame>
        <population>All treated participants&#xD;
Study terminated, data not reported due to privacy reasons</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Part 1)</title>
            <description>BMS-986277 IV 3 X 10^10&#xD;
Cycle 1 of BMS-986277 will be administered as a single IV infusion (D1) before proceeding to sequential dosing (consisting of 3 doses administered on Days 15, 17, and 19). A minimum of 24 hours is required between doses of BMS-986277.</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Part 1)</title>
            <description>BMS-986277 IV 3 X 10^11&#xD;
Cycle 1 of BMS-986277 will be administered as a single IV infusion (D1) before proceeding to sequential dosing (consisting of 3 doses administered on Days 15, 17, and 19). A minimum of 24 hours is required between doses of BMS-986277.</description>
          </group>
          <group group_id="O3">
            <title>Arm C (Part 1)</title>
            <description>BMS-986277 IV 1 X 10^12&#xD;
Cycle 1 of BMS-986277 will be administered as a single IV infusion (D1) before proceeding to sequential dosing (consisting of 3 doses administered on Days 15, 17, and 19). A minimum of 24 hours is required between doses of BMS-986277.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Clinical Laboratory Test Abnormality</title>
          <description>Number of participants who experienced a clinical laboratory test abnormality during the course of the study.</description>
          <population>All treated participants&#xD;
Study terminated, data not reported due to privacy reasons</population>
          <units>Number of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Study terminated, data not reported due to privacy reasons</measurement>
                    <measurement group_id="O2" value="NA">Study terminated, data not reported due to privacy reasons</measurement>
                    <measurement group_id="O3" value="NA">Study terminated, data not reported due to privacy reasons</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With a Vital Sign Abnormality or Other Safety Biomarkers</title>
        <description>Number of participants who experienced a vital sign abnormality or other safety biomarkers during the course of the study.</description>
        <time_frame>from first dose to 60 days post last dose, assessed up to February 2020 (approx. 26 months)</time_frame>
        <population>All treated participants&#xD;
Study terminated, data not reported due to privacy reasons</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Part 1)</title>
            <description>BMS-986277 IV 3 X 10^10&#xD;
Cycle 1 of BMS-986277 will be administered as a single IV infusion (D1) before proceeding to sequential dosing (consisting of 3 doses administered on Days 15, 17, and 19). A minimum of 24 hours is required between doses of BMS-986277.</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Part 1)</title>
            <description>BMS-986277 IV 3 X 10^11&#xD;
Cycle 1 of BMS-986277 will be administered as a single IV infusion (D1) before proceeding to sequential dosing (consisting of 3 doses administered on Days 15, 17, and 19). A minimum of 24 hours is required between doses of BMS-986277.</description>
          </group>
          <group group_id="O3">
            <title>Arm C (Part 1)</title>
            <description>BMS-986277 IV 1 X 10^12&#xD;
Cycle 1 of BMS-986277 will be administered as a single IV infusion (D1) before proceeding to sequential dosing (consisting of 3 doses administered on Days 15, 17, and 19). A minimum of 24 hours is required between doses of BMS-986277.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Vital Sign Abnormality or Other Safety Biomarkers</title>
          <description>Number of participants who experienced a vital sign abnormality or other safety biomarkers during the course of the study.</description>
          <population>All treated participants&#xD;
Study terminated, data not reported due to privacy reasons</population>
          <units>Number of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Study terminated, data not reported due to privacy reasons</measurement>
                    <measurement group_id="O2" value="NA">Study terminated, data not reported due to privacy reasons</measurement>
                    <measurement group_id="O3" value="NA">Study terminated, data not reported due to privacy reasons</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Response Rate (ORR)</title>
        <description>ORR is defined as the proportion of all treated participants whose BOR is either CR or PR. BOR was determined by investigators for the reported data.&#xD;
Estimate of ORR and corresponding 2-sided exact 95% CI using the Clopper-Pearson method</description>
        <time_frame>at Weeks 8, 16 and 24</time_frame>
        <population>All treated participants&#xD;
Study terminated, data not reported due to privacy reasons</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Part 1)</title>
            <description>BMS-986277 IV 3 X 10^10&#xD;
Cycle 1 of BMS-986277 will be administered as a single IV infusion (D1) before proceeding to sequential dosing (consisting of 3 doses administered on Days 15, 17, and 19). A minimum of 24 hours is required between doses of BMS-986277.</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Part 1)</title>
            <description>BMS-986277 IV 3 X 10^11&#xD;
Cycle 1 of BMS-986277 will be administered as a single IV infusion (D1) before proceeding to sequential dosing (consisting of 3 doses administered on Days 15, 17, and 19). A minimum of 24 hours is required between doses of BMS-986277.</description>
          </group>
          <group group_id="O3">
            <title>Arm C (Part 1)</title>
            <description>BMS-986277 IV 1 X 10^12&#xD;
Cycle 1 of BMS-986277 will be administered as a single IV infusion (D1) before proceeding to sequential dosing (consisting of 3 doses administered on Days 15, 17, and 19). A minimum of 24 hours is required between doses of BMS-986277.</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate (ORR)</title>
          <description>ORR is defined as the proportion of all treated participants whose BOR is either CR or PR. BOR was determined by investigators for the reported data.&#xD;
Estimate of ORR and corresponding 2-sided exact 95% CI using the Clopper-Pearson method</description>
          <population>All treated participants&#xD;
Study terminated, data not reported due to privacy reasons</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Study terminated, data not reported due to privacy reasons</measurement>
                    <measurement group_id="O2" value="NA">Study terminated, data not reported due to privacy reasons</measurement>
                    <measurement group_id="O3" value="NA">Study terminated, data not reported due to privacy reasons</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Control Rate (DCR)</title>
        <description>DCR includes complete response (CR), partial response (PR), and stable disease (SD).&#xD;
Estimate of DCR and corresponding 2-sided exact 95% CI using the Clopper-Pearson method</description>
        <time_frame>at Weeks 8, 16 and 24</time_frame>
        <population>All treated participants&#xD;
Study terminated, data not reported due to privacy reasons</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Part 1)</title>
            <description>BMS-986277 IV 3 X 10^10&#xD;
Cycle 1 of BMS-986277 will be administered as a single IV infusion (D1) before proceeding to sequential dosing (consisting of 3 doses administered on Days 15, 17, and 19). A minimum of 24 hours is required between doses of BMS-986277.</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Part 1)</title>
            <description>BMS-986277 IV 3 X 10^11&#xD;
Cycle 1 of BMS-986277 will be administered as a single IV infusion (D1) before proceeding to sequential dosing (consisting of 3 doses administered on Days 15, 17, and 19). A minimum of 24 hours is required between doses of BMS-986277.</description>
          </group>
          <group group_id="O3">
            <title>Arm C (Part 1)</title>
            <description>BMS-986277 IV 1 X 10^12&#xD;
Cycle 1 of BMS-986277 will be administered as a single IV infusion (D1) before proceeding to sequential dosing (consisting of 3 doses administered on Days 15, 17, and 19). A minimum of 24 hours is required between doses of BMS-986277.</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Control Rate (DCR)</title>
          <description>DCR includes complete response (CR), partial response (PR), and stable disease (SD).&#xD;
Estimate of DCR and corresponding 2-sided exact 95% CI using the Clopper-Pearson method</description>
          <population>All treated participants&#xD;
Study terminated, data not reported due to privacy reasons</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Study terminated, data not reported due to privacy reasons</measurement>
                    <measurement group_id="O2" value="NA">Study terminated, data not reported due to privacy reasons</measurement>
                    <measurement group_id="O3" value="NA">Study terminated, data not reported due to privacy reasons</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Duration of Response (mDOR)</title>
        <description>DOR for a participant with a BOR of CR or PR is defined as the time between the date of first response and the date of the first objectively documented tumor progression per RECIST v1.1/PCWG3 or death, whichever occurs first.&#xD;
Estimate by the Kaplan-Meier method and corresponding 2-sided 95% CI using Brookmeyer and Crowley methodology (using log-log transformation)</description>
        <time_frame>at Weeks 8, 16 and 24</time_frame>
        <population>All treated participants&#xD;
Study terminated, data not reported due to privacy reasons</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Part 1)</title>
            <description>BMS-986277 IV 3 X 10^10&#xD;
Cycle 1 of BMS-986277 will be administered as a single IV infusion (D1) before proceeding to sequential dosing (consisting of 3 doses administered on Days 15, 17, and 19). A minimum of 24 hours is required between doses of BMS-986277.</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Part 1)</title>
            <description>BMS-986277 IV 3 X 10^11&#xD;
Cycle 1 of BMS-986277 will be administered as a single IV infusion (D1) before proceeding to sequential dosing (consisting of 3 doses administered on Days 15, 17, and 19). A minimum of 24 hours is required between doses of BMS-986277.</description>
          </group>
          <group group_id="O3">
            <title>Arm C (Part 1)</title>
            <description>BMS-986277 IV 1 X 10^12&#xD;
Cycle 1 of BMS-986277 will be administered as a single IV infusion (D1) before proceeding to sequential dosing (consisting of 3 doses administered on Days 15, 17, and 19). A minimum of 24 hours is required between doses of BMS-986277.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Duration of Response (mDOR)</title>
          <description>DOR for a participant with a BOR of CR or PR is defined as the time between the date of first response and the date of the first objectively documented tumor progression per RECIST v1.1/PCWG3 or death, whichever occurs first.&#xD;
Estimate by the Kaplan-Meier method and corresponding 2-sided 95% CI using Brookmeyer and Crowley methodology (using log-log transformation)</description>
          <population>All treated participants&#xD;
Study terminated, data not reported due to privacy reasons</population>
          <units>Number of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Study terminated, data not reported due to privacy reasons</measurement>
                    <measurement group_id="O2" value="NA">Study terminated, data not reported due to privacy reasons</measurement>
                    <measurement group_id="O3" value="NA">Study terminated, data not reported due to privacy reasons</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Progression-Free Survival (mPFS)</title>
        <description>PFS for a participant is defined as the time from the first dosing date to the date of first objectively documented disease progression or death due to any cause, whichever occurs first.&#xD;
Estimate by the Kaplan-Meier method and corresponding 2-sided 95% CI using Brookmeyer and Crowley methodology (using log-log transformation) for the median and Greenwood formula for the rate.</description>
        <time_frame>at Weeks 8, 16 and 24, to progression</time_frame>
        <population>All treated participants&#xD;
Study terminated, data not reported due to privacy reasons</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Part 1)</title>
            <description>BMS-986277 IV 3 X 10^10&#xD;
Cycle 1 of BMS-986277 will be administered as a single IV infusion (D1) before proceeding to sequential dosing (consisting of 3 doses administered on Days 15, 17, and 19). A minimum of 24 hours is required between doses of BMS-986277.</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Part 1)</title>
            <description>BMS-986277 IV 3 X 10^11&#xD;
Cycle 1 of BMS-986277 will be administered as a single IV infusion (D1) before proceeding to sequential dosing (consisting of 3 doses administered on Days 15, 17, and 19). A minimum of 24 hours is required between doses of BMS-986277.</description>
          </group>
          <group group_id="O3">
            <title>Arm C (Part 1)</title>
            <description>BMS-986277 IV 1 X 10^12&#xD;
Cycle 1 of BMS-986277 will be administered as a single IV infusion (D1) before proceeding to sequential dosing (consisting of 3 doses administered on Days 15, 17, and 19). A minimum of 24 hours is required between doses of BMS-986277.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Progression-Free Survival (mPFS)</title>
          <description>PFS for a participant is defined as the time from the first dosing date to the date of first objectively documented disease progression or death due to any cause, whichever occurs first.&#xD;
Estimate by the Kaplan-Meier method and corresponding 2-sided 95% CI using Brookmeyer and Crowley methodology (using log-log transformation) for the median and Greenwood formula for the rate.</description>
          <population>All treated participants&#xD;
Study terminated, data not reported due to privacy reasons</population>
          <units>Number of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Study terminated, data not reported due to privacy reasons</measurement>
                    <measurement group_id="O2" value="NA">Study terminated, data not reported due to privacy reasons</measurement>
                    <measurement group_id="O3" value="NA">Study terminated, data not reported due to privacy reasons</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-Free Survival Rate (PFSR)</title>
        <description>PFS for a participant is defined as the time from the first dosing date to the date of first objectively documented disease progression or death due to any cause, whichever occurs first.&#xD;
Estimate by the Kaplan-Meier method and corresponding 2-sided 95% CI using Brookmeyer and Crowley methodology (using log-log transformation) for the median and Greenwood formula for the rate.</description>
        <time_frame>at Weeks 8, 16 and 24</time_frame>
        <population>All treated participants&#xD;
Study terminated, data not reported due to privacy reasons</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Part 1)</title>
            <description>BMS-986277 IV 3 X 10^10&#xD;
Cycle 1 of BMS-986277 will be administered as a single IV infusion (D1) before proceeding to sequential dosing (consisting of 3 doses administered on Days 15, 17, and 19). A minimum of 24 hours is required between doses of BMS-986277.</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Part 1)</title>
            <description>BMS-986277 IV 3 X 10^11&#xD;
Cycle 1 of BMS-986277 will be administered as a single IV infusion (D1) before proceeding to sequential dosing (consisting of 3 doses administered on Days 15, 17, and 19). A minimum of 24 hours is required between doses of BMS-986277.</description>
          </group>
          <group group_id="O3">
            <title>Arm C (Part 1)</title>
            <description>BMS-986277 IV 1 X 10^12&#xD;
Cycle 1 of BMS-986277 will be administered as a single IV infusion (D1) before proceeding to sequential dosing (consisting of 3 doses administered on Days 15, 17, and 19). A minimum of 24 hours is required between doses of BMS-986277.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-Free Survival Rate (PFSR)</title>
          <description>PFS for a participant is defined as the time from the first dosing date to the date of first objectively documented disease progression or death due to any cause, whichever occurs first.&#xD;
Estimate by the Kaplan-Meier method and corresponding 2-sided 95% CI using Brookmeyer and Crowley methodology (using log-log transformation) for the median and Greenwood formula for the rate.</description>
          <population>All treated participants&#xD;
Study terminated, data not reported due to privacy reasons</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Study terminated, data not reported due to privacy reasons</measurement>
                    <measurement group_id="O2" value="NA">Study terminated, data not reported due to privacy reasons</measurement>
                    <measurement group_id="O3" value="NA">Study terminated, data not reported due to privacy reasons</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax</title>
        <description>Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data.&#xD;
Cmax is defined as the maximum observed blood concentration.</description>
        <time_frame>Cycle 1 (Day 1 pre-dose through Day 29, 240 hour), Cycle 2 (Day 1 pre-dose through Day 22, 408 hour); through Follow-up visits</time_frame>
        <population>All treated participants&#xD;
Study terminated, data not reported due to privacy reasons</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Part 1)</title>
            <description>BMS-986277 IV 3 X 10^10&#xD;
Cycle 1 of BMS-986277 will be administered as a single IV infusion (D1) before proceeding to sequential dosing (consisting of 3 doses administered on Days 15, 17, and 19). A minimum of 24 hours is required between doses of BMS-986277.</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Part 1)</title>
            <description>BMS-986277 IV 3 X 10^11&#xD;
Cycle 1 of BMS-986277 will be administered as a single IV infusion (D1) before proceeding to sequential dosing (consisting of 3 doses administered on Days 15, 17, and 19). A minimum of 24 hours is required between doses of BMS-986277.</description>
          </group>
          <group group_id="O3">
            <title>Arm C (Part 1)</title>
            <description>BMS-986277 IV 1 X 10^12&#xD;
Cycle 1 of BMS-986277 will be administered as a single IV infusion (D1) before proceeding to sequential dosing (consisting of 3 doses administered on Days 15, 17, and 19). A minimum of 24 hours is required between doses of BMS-986277.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax</title>
          <description>Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data.&#xD;
Cmax is defined as the maximum observed blood concentration.</description>
          <population>All treated participants&#xD;
Study terminated, data not reported due to privacy reasons</population>
          <units>g/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Study terminated, data not reported due to privacy reasons</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">Study terminated, data not reported due to privacy reasons</measurement>
                    <measurement group_id="O3" value="NA" spread="NA">Study terminated, data not reported due to privacy reasons</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax</title>
        <description>Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data.&#xD;
Tmax is defined as the time of maximum observed blood concentration.</description>
        <time_frame>Cycle 1 (Day 1 pre-dose through Day 29, 240 hour), Cycle 2 (Day 1 pre-dose through Day 22, 408 hour); through Follow-up visits</time_frame>
        <population>All treated participants&#xD;
Study terminated, data not reported due to privacy reasons</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Part 1)</title>
            <description>BMS-986277 IV 3 X 10^10&#xD;
Cycle 1 of BMS-986277 will be administered as a single IV infusion (D1) before proceeding to sequential dosing (consisting of 3 doses administered on Days 15, 17, and 19). A minimum of 24 hours is required between doses of BMS-986277.</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Part 1)</title>
            <description>BMS-986277 IV 3 X 10^11&#xD;
Cycle 1 of BMS-986277 will be administered as a single IV infusion (D1) before proceeding to sequential dosing (consisting of 3 doses administered on Days 15, 17, and 19). A minimum of 24 hours is required between doses of BMS-986277.</description>
          </group>
          <group group_id="O3">
            <title>Arm C (Part 1)</title>
            <description>BMS-986277 IV 1 X 10^12&#xD;
Cycle 1 of BMS-986277 will be administered as a single IV infusion (D1) before proceeding to sequential dosing (consisting of 3 doses administered on Days 15, 17, and 19). A minimum of 24 hours is required between doses of BMS-986277.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax</title>
          <description>Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data.&#xD;
Tmax is defined as the time of maximum observed blood concentration.</description>
          <population>All treated participants&#xD;
Study terminated, data not reported due to privacy reasons</population>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Study terminated, data not reported due to privacy reasons</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Study terminated, data not reported due to privacy reasons</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Study terminated, data not reported due to privacy reasons</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC(0-T)</title>
        <description>Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data.&#xD;
AUC(0-T) is the area under the blood concentration-time curve from time zero to time of last quantifiable concentration.</description>
        <time_frame>Cycle 1 (Day 1 pre-dose through Day 29, 240 hour), Cycle 2 (Day 1 pre-dose through Day 22, 408 hour); through Follow-up visits</time_frame>
        <population>All treated participants&#xD;
Study terminated, data not reported due to privacy reasons</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Part 1)</title>
            <description>BMS-986277 IV 3 X 10^10&#xD;
Cycle 1 of BMS-986277 will be administered as a single IV infusion (D1) before proceeding to sequential dosing (consisting of 3 doses administered on Days 15, 17, and 19). A minimum of 24 hours is required between doses of BMS-986277.</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Part 1)</title>
            <description>BMS-986277 IV 3 X 10^11&#xD;
Cycle 1 of BMS-986277 will be administered as a single IV infusion (D1) before proceeding to sequential dosing (consisting of 3 doses administered on Days 15, 17, and 19). A minimum of 24 hours is required between doses of BMS-986277.</description>
          </group>
          <group group_id="O3">
            <title>Arm C (Part 1)</title>
            <description>BMS-986277 IV 1 X 10^12&#xD;
Cycle 1 of BMS-986277 will be administered as a single IV infusion (D1) before proceeding to sequential dosing (consisting of 3 doses administered on Days 15, 17, and 19). A minimum of 24 hours is required between doses of BMS-986277.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-T)</title>
          <description>Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data.&#xD;
AUC(0-T) is the area under the blood concentration-time curve from time zero to time of last quantifiable concentration.</description>
          <population>All treated participants&#xD;
Study terminated, data not reported due to privacy reasons</population>
          <units>g.h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Study terminated, data not reported due to privacy reasons</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">Study terminated, data not reported due to privacy reasons</measurement>
                    <measurement group_id="O3" value="NA" spread="NA">Study terminated, data not reported due to privacy reasons</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC(INF)</title>
        <description>Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data.&#xD;
AUC(INF) is the area under the blood concentration-time curve from time zero extrapolated to infinite time.</description>
        <time_frame>Cycle 1 (Day 1 pre-dose through Day 29, 240 hour), Cycle 2 (Day 1 pre-dose through Day 22, 408 hour); through Follow-up visits</time_frame>
        <population>All treated participants&#xD;
Study terminated, data not reported due to privacy reasons</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Part 1)</title>
            <description>BMS-986277 IV 3 X 10^10&#xD;
Cycle 1 of BMS-986277 will be administered as a single IV infusion (D1) before proceeding to sequential dosing (consisting of 3 doses administered on Days 15, 17, and 19). A minimum of 24 hours is required between doses of BMS-986277.</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Part 1)</title>
            <description>BMS-986277 IV 3 X 10^11&#xD;
Cycle 1 of BMS-986277 will be administered as a single IV infusion (D1) before proceeding to sequential dosing (consisting of 3 doses administered on Days 15, 17, and 19). A minimum of 24 hours is required between doses of BMS-986277.</description>
          </group>
          <group group_id="O3">
            <title>Arm C (Part 1)</title>
            <description>BMS-986277 IV 1 X 10^12&#xD;
Cycle 1 of BMS-986277 will be administered as a single IV infusion (D1) before proceeding to sequential dosing (consisting of 3 doses administered on Days 15, 17, and 19). A minimum of 24 hours is required between doses of BMS-986277.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(INF)</title>
          <description>Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data.&#xD;
AUC(INF) is the area under the blood concentration-time curve from time zero extrapolated to infinite time.</description>
          <population>All treated participants&#xD;
Study terminated, data not reported due to privacy reasons</population>
          <units>g.h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Study terminated, data not reported due to privacy reasons</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">Study terminated, data not reported due to privacy reasons</measurement>
                    <measurement group_id="O3" value="NA" spread="NA">Study terminated, data not reported due to privacy reasons</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>T-HALF</title>
        <description>Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data.&#xD;
T-HALF is defined as the apparent terminal half-life.</description>
        <time_frame>Cycle 1 (Day 1 pre-dose through Day 29, 240 hour), Cycle 2 (Day 1 pre-dose through Day 22, 408 hour); through Follow-up visits</time_frame>
        <population>All treated participants&#xD;
Study terminated, data not reported due to privacy reasons</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Part 1)</title>
            <description>BMS-986277 IV 3 X 10^10&#xD;
Cycle 1 of BMS-986277 will be administered as a single IV infusion (D1) before proceeding to sequential dosing (consisting of 3 doses administered on Days 15, 17, and 19). A minimum of 24 hours is required between doses of BMS-986277.</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Part 1)</title>
            <description>BMS-986277 IV 3 X 10^11&#xD;
Cycle 1 of BMS-986277 will be administered as a single IV infusion (D1) before proceeding to sequential dosing (consisting of 3 doses administered on Days 15, 17, and 19). A minimum of 24 hours is required between doses of BMS-986277.</description>
          </group>
          <group group_id="O3">
            <title>Arm C (Part 1)</title>
            <description>BMS-986277 IV 1 X 10^12&#xD;
Cycle 1 of BMS-986277 will be administered as a single IV infusion (D1) before proceeding to sequential dosing (consisting of 3 doses administered on Days 15, 17, and 19). A minimum of 24 hours is required between doses of BMS-986277.</description>
          </group>
        </group_list>
        <measure>
          <title>T-HALF</title>
          <description>Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data.&#xD;
T-HALF is defined as the apparent terminal half-life.</description>
          <population>All treated participants&#xD;
Study terminated, data not reported due to privacy reasons</population>
          <units>hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Study terminated, data not reported due to privacy reasons</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">Study terminated, data not reported due to privacy reasons</measurement>
                    <measurement group_id="O3" value="NA" spread="NA">Study terminated, data not reported due to privacy reasons</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CLT</title>
        <description>Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data.&#xD;
CLT is defined as the total body clearance.</description>
        <time_frame>Cycle 1 (Day 1 pre-dose through Day 29, 240 hour), Cycle 2 (Day 1 pre-dose through Day 22, 408 hour); through Follow-up visits</time_frame>
        <population>All treated participants&#xD;
Study terminated, data not reported due to privacy reasons</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Part 1)</title>
            <description>BMS-986277 IV 3 X 10^10&#xD;
Cycle 1 of BMS-986277 will be administered as a single IV infusion (D1) before proceeding to sequential dosing (consisting of 3 doses administered on Days 15, 17, and 19). A minimum of 24 hours is required between doses of BMS-986277.</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Part 1)</title>
            <description>BMS-986277 IV 3 X 10^11&#xD;
Cycle 1 of BMS-986277 will be administered as a single IV infusion (D1) before proceeding to sequential dosing (consisting of 3 doses administered on Days 15, 17, and 19). A minimum of 24 hours is required between doses of BMS-986277.</description>
          </group>
          <group group_id="O3">
            <title>Arm C (Part 1)</title>
            <description>BMS-986277 IV 1 X 10^12&#xD;
Cycle 1 of BMS-986277 will be administered as a single IV infusion (D1) before proceeding to sequential dosing (consisting of 3 doses administered on Days 15, 17, and 19). A minimum of 24 hours is required between doses of BMS-986277.</description>
          </group>
        </group_list>
        <measure>
          <title>CLT</title>
          <description>Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data.&#xD;
CLT is defined as the total body clearance.</description>
          <population>All treated participants&#xD;
Study terminated, data not reported due to privacy reasons</population>
          <units>liter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Study terminated, data not reported due to privacy reasons</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">Study terminated, data not reported due to privacy reasons</measurement>
                    <measurement group_id="O3" value="NA" spread="NA">Study terminated, data not reported due to privacy reasons</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vss</title>
        <description>Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data.&#xD;
Vss is defined as the volume of distribution at steady-state.</description>
        <time_frame>Cycle 1 (Day 1 pre-dose through Day 29, 240 hour), Cycle 2 (Day 1 pre-dose through Day 22, 408 hour); through Follow-up visits</time_frame>
        <population>All treated participants&#xD;
Study terminated, data not reported due to privacy reasons</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Part 1)</title>
            <description>BMS-986277 IV 3 X 10^10&#xD;
Cycle 1 of BMS-986277 will be administered as a single IV infusion (D1) before proceeding to sequential dosing (consisting of 3 doses administered on Days 15, 17, and 19). A minimum of 24 hours is required between doses of BMS-986277.</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Part 1)</title>
            <description>BMS-986277 IV 3 X 10^11&#xD;
Cycle 1 of BMS-986277 will be administered as a single IV infusion (D1) before proceeding to sequential dosing (consisting of 3 doses administered on Days 15, 17, and 19). A minimum of 24 hours is required between doses of BMS-986277.</description>
          </group>
          <group group_id="O3">
            <title>Arm C (Part 1)</title>
            <description>BMS-986277 IV 1 X 10^12&#xD;
Cycle 1 of BMS-986277 will be administered as a single IV infusion (D1) before proceeding to sequential dosing (consisting of 3 doses administered on Days 15, 17, and 19). A minimum of 24 hours is required between doses of BMS-986277.</description>
          </group>
        </group_list>
        <measure>
          <title>Vss</title>
          <description>Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data.&#xD;
Vss is defined as the volume of distribution at steady-state.</description>
          <population>All treated participants&#xD;
Study terminated, data not reported due to privacy reasons</population>
          <units>liter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Study terminated, data not reported due to privacy reasons</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">Study terminated, data not reported due to privacy reasons</measurement>
                    <measurement group_id="O3" value="NA" spread="NA">Study terminated, data not reported due to privacy reasons</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vz</title>
        <description>Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data.&#xD;
Vz is defined as the volume of distribution of the elimination phase.</description>
        <time_frame>Cycle 1 (Day 1 pre-dose through Day 29, 240 hour), Cycle 2 (Day 1 pre-dose through Day 22, 408 hour); through Follow-up visits</time_frame>
        <population>All treated participants&#xD;
Study terminated, data not reported due to privacy reasons</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Part 1)</title>
            <description>BMS-986277 IV 3 X 10^10&#xD;
Cycle 1 of BMS-986277 will be administered as a single IV infusion (D1) before proceeding to sequential dosing (consisting of 3 doses administered on Days 15, 17, and 19). A minimum of 24 hours is required between doses of BMS-986277.</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Part 1)</title>
            <description>BMS-986277 IV 3 X 10^11&#xD;
Cycle 1 of BMS-986277 will be administered as a single IV infusion (D1) before proceeding to sequential dosing (consisting of 3 doses administered on Days 15, 17, and 19). A minimum of 24 hours is required between doses of BMS-986277.</description>
          </group>
          <group group_id="O3">
            <title>Arm C (Part 1)</title>
            <description>BMS-986277 IV 1 X 10^12&#xD;
Cycle 1 of BMS-986277 will be administered as a single IV infusion (D1) before proceeding to sequential dosing (consisting of 3 doses administered on Days 15, 17, and 19). A minimum of 24 hours is required between doses of BMS-986277.</description>
          </group>
        </group_list>
        <measure>
          <title>Vz</title>
          <description>Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data.&#xD;
Vz is defined as the volume of distribution of the elimination phase.</description>
          <population>All treated participants&#xD;
Study terminated, data not reported due to privacy reasons</population>
          <units>liter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Study terminated, data not reported due to privacy reasons</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">Study terminated, data not reported due to privacy reasons</measurement>
                    <measurement group_id="O3" value="NA" spread="NA">Study terminated, data not reported due to privacy reasons</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC(0-48)</title>
        <description>Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data.&#xD;
AUC(0-T) is the area under the blood concentration-time curve from time zero to 48 hours postdose</description>
        <time_frame>Cycle 1 (from time zero to 48 hours postdose)</time_frame>
        <population>All treated participants&#xD;
Study terminated, data not reported due to privacy reasons</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Part 1)</title>
            <description>BMS-986277 IV 3 X 10^10&#xD;
Cycle 1 of BMS-986277 will be administered as a single IV infusion (D1) before proceeding to sequential dosing (consisting of 3 doses administered on Days 15, 17, and 19). A minimum of 24 hours is required between doses of BMS-986277.</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Part 1)</title>
            <description>BMS-986277 IV 3 X 10^11&#xD;
Cycle 1 of BMS-986277 will be administered as a single IV infusion (D1) before proceeding to sequential dosing (consisting of 3 doses administered on Days 15, 17, and 19). A minimum of 24 hours is required between doses of BMS-986277.</description>
          </group>
          <group group_id="O3">
            <title>Arm C (Part 1)</title>
            <description>BMS-986277 IV 1 X 10^12&#xD;
Cycle 1 of BMS-986277 will be administered as a single IV infusion (D1) before proceeding to sequential dosing (consisting of 3 doses administered on Days 15, 17, and 19). A minimum of 24 hours is required between doses of BMS-986277.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-48)</title>
          <description>Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data.&#xD;
AUC(0-T) is the area under the blood concentration-time curve from time zero to 48 hours postdose</description>
          <population>All treated participants&#xD;
Study terminated, data not reported due to privacy reasons</population>
          <units>g.h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Study terminated, data not reported due to privacy reasons</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">Study terminated, data not reported due to privacy reasons</measurement>
                    <measurement group_id="O3" value="NA" spread="NA">Study terminated, data not reported due to privacy reasons</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC(0-8)</title>
        <description>Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data.&#xD;
AUC(0-T) is the area under the blood concentration-time curve from time zero to 8 hours postdose</description>
        <time_frame>Cycle 1 (from time zero to 8 hours postdose)</time_frame>
        <population>All treated participants&#xD;
Study terminated, data not reported due to privacy reasons</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Part 1)</title>
            <description>BMS-986277 IV 3 X 10^10&#xD;
Cycle 1 of BMS-986277 will be administered as a single IV infusion (D1) before proceeding to sequential dosing (consisting of 3 doses administered on Days 15, 17, and 19). A minimum of 24 hours is required between doses of BMS-986277.</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Part 1)</title>
            <description>BMS-986277 IV 3 X 10^11&#xD;
Cycle 1 of BMS-986277 will be administered as a single IV infusion (D1) before proceeding to sequential dosing (consisting of 3 doses administered on Days 15, 17, and 19). A minimum of 24 hours is required between doses of BMS-986277.</description>
          </group>
          <group group_id="O3">
            <title>Arm C (Part 1)</title>
            <description>BMS-986277 IV 1 X 10^12&#xD;
Cycle 1 of BMS-986277 will be administered as a single IV infusion (D1) before proceeding to sequential dosing (consisting of 3 doses administered on Days 15, 17, and 19). A minimum of 24 hours is required between doses of BMS-986277.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-8)</title>
          <description>Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data.&#xD;
AUC(0-T) is the area under the blood concentration-time curve from time zero to 8 hours postdose</description>
          <population>All treated participants&#xD;
Study terminated, data not reported due to privacy reasons</population>
          <units>g.h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Study terminated, data not reported due to privacy reasons</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">Study terminated, data not reported due to privacy reasons</measurement>
                    <measurement group_id="O3" value="NA" spread="NA">Study terminated, data not reported due to privacy reasons</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>C48</title>
        <description>Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data.&#xD;
C48 is defined as the blood concentration at 48 hours postdose.</description>
        <time_frame>Cycle 1 at 48 hours postdose</time_frame>
        <population>All treated participants&#xD;
Study terminated, data not reported due to privacy reasons</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Part 1)</title>
            <description>BMS-986277 IV 3 X 10^10&#xD;
Cycle 1 of BMS-986277 will be administered as a single IV infusion (D1) before proceeding to sequential dosing (consisting of 3 doses administered on Days 15, 17, and 19). A minimum of 24 hours is required between doses of BMS-986277.</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Part 1)</title>
            <description>BMS-986277 IV 3 X 10^11&#xD;
Cycle 1 of BMS-986277 will be administered as a single IV infusion (D1) before proceeding to sequential dosing (consisting of 3 doses administered on Days 15, 17, and 19). A minimum of 24 hours is required between doses of BMS-986277.</description>
          </group>
          <group group_id="O3">
            <title>Arm C (Part 1)</title>
            <description>BMS-986277 IV 1 X 10^12&#xD;
Cycle 1 of BMS-986277 will be administered as a single IV infusion (D1) before proceeding to sequential dosing (consisting of 3 doses administered on Days 15, 17, and 19). A minimum of 24 hours is required between doses of BMS-986277.</description>
          </group>
        </group_list>
        <measure>
          <title>C48</title>
          <description>Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data.&#xD;
C48 is defined as the blood concentration at 48 hours postdose.</description>
          <population>All treated participants&#xD;
Study terminated, data not reported due to privacy reasons</population>
          <units>g/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Study terminated, data not reported due to privacy reasons</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">Study terminated, data not reported due to privacy reasons</measurement>
                    <measurement group_id="O3" value="NA" spread="NA">Study terminated, data not reported due to privacy reasons</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Css-avg</title>
        <description>Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data.&#xD;
Css-avg is defined as the average blood concentration over a dosing interval at steady state (AUC[0-48]/48).</description>
        <time_frame>Cycle 1 (from time zero to 48 hours postdose)</time_frame>
        <population>All treated participants&#xD;
Study terminated, data not reported due to privacy reasons</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Part 1)</title>
            <description>BMS-986277 IV 3 X 10^10&#xD;
Cycle 1 of BMS-986277 will be administered as a single IV infusion (D1) before proceeding to sequential dosing (consisting of 3 doses administered on Days 15, 17, and 19). A minimum of 24 hours is required between doses of BMS-986277.</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Part 1)</title>
            <description>BMS-986277 IV 3 X 10^11&#xD;
Cycle 1 of BMS-986277 will be administered as a single IV infusion (D1) before proceeding to sequential dosing (consisting of 3 doses administered on Days 15, 17, and 19). A minimum of 24 hours is required between doses of BMS-986277.</description>
          </group>
          <group group_id="O3">
            <title>Arm C (Part 1)</title>
            <description>BMS-986277 IV 1 X 10^12&#xD;
Cycle 1 of BMS-986277 will be administered as a single IV infusion (D1) before proceeding to sequential dosing (consisting of 3 doses administered on Days 15, 17, and 19). A minimum of 24 hours is required between doses of BMS-986277.</description>
          </group>
        </group_list>
        <measure>
          <title>Css-avg</title>
          <description>Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data.&#xD;
Css-avg is defined as the average blood concentration over a dosing interval at steady state (AUC[0-48]/48).</description>
          <population>All treated participants&#xD;
Study terminated, data not reported due to privacy reasons</population>
          <units>g/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Study terminated, data not reported due to privacy reasons</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">Study terminated, data not reported due to privacy reasons</measurement>
                    <measurement group_id="O3" value="NA" spread="NA">Study terminated, data not reported due to privacy reasons</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AI_AUC</title>
        <description>Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data.&#xD;
AUC accumulation index; ratio of AUC(0-48) on Cycle 1 Day 19 to AUC(0-48) on Cycle 1 Day 15 for monotherapy.</description>
        <time_frame>Cycle 1 (Day 19, Day 15)</time_frame>
        <population>All treated participants&#xD;
Study terminated, data not reported due to privacy reasons</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Part 1)</title>
            <description>BMS-986277 IV 3 X 10^10&#xD;
Cycle 1 of BMS-986277 will be administered as a single IV infusion (D1) before proceeding to sequential dosing (consisting of 3 doses administered on Days 15, 17, and 19). A minimum of 24 hours is required between doses of BMS-986277.</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Part 1)</title>
            <description>BMS-986277 IV 3 X 10^11&#xD;
Cycle 1 of BMS-986277 will be administered as a single IV infusion (D1) before proceeding to sequential dosing (consisting of 3 doses administered on Days 15, 17, and 19). A minimum of 24 hours is required between doses of BMS-986277.</description>
          </group>
          <group group_id="O3">
            <title>Arm C (Part 1)</title>
            <description>BMS-986277 IV 1 X 10^12&#xD;
Cycle 1 of BMS-986277 will be administered as a single IV infusion (D1) before proceeding to sequential dosing (consisting of 3 doses administered on Days 15, 17, and 19). A minimum of 24 hours is required between doses of BMS-986277.</description>
          </group>
        </group_list>
        <measure>
          <title>AI_AUC</title>
          <description>Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data.&#xD;
AUC accumulation index; ratio of AUC(0-48) on Cycle 1 Day 19 to AUC(0-48) on Cycle 1 Day 15 for monotherapy.</description>
          <population>All treated participants&#xD;
Study terminated, data not reported due to privacy reasons</population>
          <units>ratio AUC(0-48),C1D19 to AUC(0-48),C1D15</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Study terminated, data not reported due to privacy reasons</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">Study terminated, data not reported due to privacy reasons</measurement>
                    <measurement group_id="O3" value="NA" spread="NA">Study terminated, data not reported due to privacy reasons</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AI_Cmax</title>
        <description>Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data.&#xD;
Cmax accumulation index; ratio of Cmax on Cycle 1 Day 19 to Cmax on Cycle 1 Day 15 for monotherapy.</description>
        <time_frame>Cycle 1 (Day 19, Day 15)</time_frame>
        <population>All treated participants&#xD;
Study terminated, data not reported due to privacy reasons</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Part 1)</title>
            <description>BMS-986277 IV 3 X 10^10&#xD;
Cycle 1 of BMS-986277 will be administered as a single IV infusion (D1) before proceeding to sequential dosing (consisting of 3 doses administered on Days 15, 17, and 19). A minimum of 24 hours is required between doses of BMS-986277.</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Part 1)</title>
            <description>BMS-986277 IV 3 X 10^11&#xD;
Cycle 1 of BMS-986277 will be administered as a single IV infusion (D1) before proceeding to sequential dosing (consisting of 3 doses administered on Days 15, 17, and 19). A minimum of 24 hours is required between doses of BMS-986277.</description>
          </group>
          <group group_id="O3">
            <title>Arm C (Part 1)</title>
            <description>BMS-986277 IV 1 X 10^12&#xD;
Cycle 1 of BMS-986277 will be administered as a single IV infusion (D1) before proceeding to sequential dosing (consisting of 3 doses administered on Days 15, 17, and 19). A minimum of 24 hours is required between doses of BMS-986277.</description>
          </group>
        </group_list>
        <measure>
          <title>AI_Cmax</title>
          <description>Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data.&#xD;
Cmax accumulation index; ratio of Cmax on Cycle 1 Day 19 to Cmax on Cycle 1 Day 15 for monotherapy.</description>
          <population>All treated participants&#xD;
Study terminated, data not reported due to privacy reasons</population>
          <units>ratio of Cmax,C1D19 to Cmax,C1D15</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Study terminated, data not reported due to privacy reasons</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">Study terminated, data not reported due to privacy reasons</measurement>
                    <measurement group_id="O3" value="NA" spread="NA">Study terminated, data not reported due to privacy reasons</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>T-HALFeff</title>
        <description>Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data.&#xD;
T-HALFeff is defined as effective elimination half-life that explains the degree of accumulation observed for a specific exposure measure (exposure measure includes AUC, Cmax)</description>
        <time_frame>Cycle 1 (Day 1 pre-dose through Day 29, 240 hour), Cycle 2 (Day 1 pre-dose through Day 22, 408 hour); through Follow-up visits</time_frame>
        <population>All treated participants&#xD;
Study terminated, data not reported due to privacy reasons</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Part 1)</title>
            <description>BMS-986277 IV 3 X 10^10&#xD;
Cycle 1 of BMS-986277 will be administered as a single IV infusion (D1) before proceeding to sequential dosing (consisting of 3 doses administered on Days 15, 17, and 19). A minimum of 24 hours is required between doses of BMS-986277.</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Part 1)</title>
            <description>BMS-986277 IV 3 X 10^11&#xD;
Cycle 1 of BMS-986277 will be administered as a single IV infusion (D1) before proceeding to sequential dosing (consisting of 3 doses administered on Days 15, 17, and 19). A minimum of 24 hours is required between doses of BMS-986277.</description>
          </group>
          <group group_id="O3">
            <title>Arm C (Part 1)</title>
            <description>BMS-986277 IV 1 X 10^12&#xD;
Cycle 1 of BMS-986277 will be administered as a single IV infusion (D1) before proceeding to sequential dosing (consisting of 3 doses administered on Days 15, 17, and 19). A minimum of 24 hours is required between doses of BMS-986277.</description>
          </group>
        </group_list>
        <measure>
          <title>T-HALFeff</title>
          <description>Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data.&#xD;
T-HALFeff is defined as effective elimination half-life that explains the degree of accumulation observed for a specific exposure measure (exposure measure includes AUC, Cmax)</description>
          <population>All treated participants&#xD;
Study terminated, data not reported due to privacy reasons</population>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Study terminated, data not reported due to privacy reasons</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Study terminated, data not reported due to privacy reasons</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Study terminated, data not reported due to privacy reasons</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ctrough</title>
        <description>Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data.&#xD;
Ctrough is defined as the trough observed blood concentration.</description>
        <time_frame>Cycle 1 (Day 1 pre-dose through Day 29, 240 hour), Cycle 2 (Day 1 pre-dose through Day 22, 408 hour); through Follow-up visits</time_frame>
        <population>All treated participants&#xD;
Study terminated, data not reported due to privacy reasons</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Part 1)</title>
            <description>BMS-986277 IV 3 X 10^10&#xD;
Cycle 1 of BMS-986277 will be administered as a single IV infusion (D1) before proceeding to sequential dosing (consisting of 3 doses administered on Days 15, 17, and 19). A minimum of 24 hours is required between doses of BMS-986277.</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Part 1)</title>
            <description>BMS-986277 IV 3 X 10^11&#xD;
Cycle 1 of BMS-986277 will be administered as a single IV infusion (D1) before proceeding to sequential dosing (consisting of 3 doses administered on Days 15, 17, and 19). A minimum of 24 hours is required between doses of BMS-986277.</description>
          </group>
          <group group_id="O3">
            <title>Arm C (Part 1)</title>
            <description>BMS-986277 IV 1 X 10^12&#xD;
Cycle 1 of BMS-986277 will be administered as a single IV infusion (D1) before proceeding to sequential dosing (consisting of 3 doses administered on Days 15, 17, and 19). A minimum of 24 hours is required between doses of BMS-986277.</description>
          </group>
        </group_list>
        <measure>
          <title>Ctrough</title>
          <description>Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data.&#xD;
Ctrough is defined as the trough observed blood concentration.</description>
          <population>All treated participants&#xD;
Study terminated, data not reported due to privacy reasons</population>
          <units>g/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Study terminated, data not reported due to privacy reasons</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">Study terminated, data not reported due to privacy reasons</measurement>
                    <measurement group_id="O3" value="NA" spread="NA">Study terminated, data not reported due to privacy reasons</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With a Positive Antibody-Drug-Antibody (ADA) Response</title>
        <description>Baseline ADA-positive participant is defined as a participant who has an ADA-detected sample at baseline.&#xD;
ADA-positive participant is a participant with at least 1 ADA-positive sample relative to baseline after initiation of the treatment.&#xD;
Frequency distribution of baseline ADA-positive participants and ADA-positive participants after initiation of the treatment</description>
        <time_frame>Cycle 1 (Day 1 pre-dose through Day 29, 240 hour), Cycle 2 (Day 1 pre-dose through Day 22, 408 hour); through Follow-up visits</time_frame>
        <population>All treated participants&#xD;
Study terminated, data not reported due to privacy reasons</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Part 1)</title>
            <description>BMS-986277 IV 3 X 10^10&#xD;
Cycle 1 of BMS-986277 will be administered as a single IV infusion (D1) before proceeding to sequential dosing (consisting of 3 doses administered on Days 15, 17, and 19). A minimum of 24 hours is required between doses of BMS-986277.</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Part 1)</title>
            <description>BMS-986277 IV 3 X 10^11&#xD;
Cycle 1 of BMS-986277 will be administered as a single IV infusion (D1) before proceeding to sequential dosing (consisting of 3 doses administered on Days 15, 17, and 19). A minimum of 24 hours is required between doses of BMS-986277.</description>
          </group>
          <group group_id="O3">
            <title>Arm C (Part 1)</title>
            <description>BMS-986277 IV 1 X 10^12&#xD;
Cycle 1 of BMS-986277 will be administered as a single IV infusion (D1) before proceeding to sequential dosing (consisting of 3 doses administered on Days 15, 17, and 19). A minimum of 24 hours is required between doses of BMS-986277.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Positive Antibody-Drug-Antibody (ADA) Response</title>
          <description>Baseline ADA-positive participant is defined as a participant who has an ADA-detected sample at baseline.&#xD;
ADA-positive participant is a participant with at least 1 ADA-positive sample relative to baseline after initiation of the treatment.&#xD;
Frequency distribution of baseline ADA-positive participants and ADA-positive participants after initiation of the treatment</description>
          <population>All treated participants&#xD;
Study terminated, data not reported due to privacy reasons</population>
          <units>Number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Study terminated, data not reported due to privacy reasons</measurement>
                    <measurement group_id="O2" value="NA">Study terminated, data not reported due to privacy reasons</measurement>
                    <measurement group_id="O3" value="NA">Study terminated, data not reported due to privacy reasons</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AEs/SAEs are collected from the first dose date until the last dose date + 100 days, assessed up to February 2020 (approx. 26 months)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Arm A (Part 1)</title>
          <description>BMS-986277 IV 3 X 10^10&#xD;
Cycle 1 of BMS-986277 will be administered as a single IV infusion (D1) before proceeding to sequential dosing (consisting of 3 doses administered on Days 15, 17, and 19). A minimum of 24 hours is required between doses of BMS-986277.</description>
        </group>
        <group group_id="E2">
          <title>Arm B (Part 1)</title>
          <description>BMS-986277 IV 3 X 10^11&#xD;
Cycle 1 of BMS-986277 will be administered as a single IV infusion (D1) before proceeding to sequential dosing (consisting of 3 doses administered on Days 15, 17, and 19). A minimum of 24 hours is required between doses of BMS-986277.</description>
        </group>
        <group group_id="E3">
          <title>Arm C (Part 1)</title>
          <description>BMS-986277 IV 1 X 10^12&#xD;
Cycle 1 of BMS-986277 will be administered as a single IV infusion (D1) before proceeding to sequential dosing (consisting of 3 doses administered on Days 15, 17, and 19). A minimum of 24 hours is required between doses of BMS-986277.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 22.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Cytokine release syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Malignant neoplasm progression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 22.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Lip ulceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Cytokine release syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Amylase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertonic bladder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Micturition urgency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Haematospermia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Bristol-Myers Squibb Study Director</name_or_title>
      <organization>Bristol-Myers Squibb</organization>
      <phone>please email:</phone>
      <email>Clinical.Trials@bms.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

